NADSYN1 and neoplasm: NMRK1 loss via either gene knock-out or knockdown decreased cellular NAD levels in FK866-treated, NAR-supplemented tumor cells (Fig. 6h, i and Supplementary Fig. 8g), as did NADSYN1 knock-out (Fig. 6j, k).